Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products

CAR-T Digest - August 2020

13 January 2026: Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products

Mabion S.A. and Celon Pharma S.A. announced plans to initiate a collaboration in the development of antibody–drug conjugate products, formalised through the signing of a Letter of Intent that outlines a framework for integrated ADC development
Under the proposed model, Mabion will act as the prime contractor with responsibility for overall project execution, including protein development, manufacturing, analytics, and project management, while Celon Pharma will contribute its expertise in conjugation processes, proprietary linker technology, and conjugation chemistry optimization
The collaboration is designed to be flexible, supporting both client-commissioned projects led by Mabion as well as co-development programs in which both companies share research and development responsibilities, with the potential for future licensing of Celon Pharma’s conjugation technology to Mabion
The parties aim to execute a Master Service Agreement by April 30, 2026, with individual statements of work to be agreed as specific client or project opportunities arise, allowing the partnership to scale in line with business demand
By combining Mabion’s strengths in protein engineering and advanced analytics with Celon Pharma’s conjugation know-how, the collaboration is expected to provide clients with an end-to-end ADC development pathway, accelerating the advancement of next-generation ADC therapies with strong commercial potential